Skip to main content
Clinical Trials/NCT04573452
NCT04573452CompletedNot Applicable

The Role of Galectin-3 in the Pathogenesis and Prediction of Placenta Accreta

Assiut University1 site in 1 country62 target enrollmentStarted: October 1, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
62
Locations
1
Primary Endpoint
Galactin 3 level in the blood

Study Overview

Brief Summary

Galectins are a family of carbohydrate-binding proteins that have a high affinity to galactosides, its protein portion is located in the nucleus and the cytoplasm with its carbohydrate recognition domain which has high ability to be glycosylated inside or outside the cell.

They are expressed by vascular endothelium, immune cells (macrophages, neutrophils, and mast cells), uterus, placenta, cardiac muscle, liver, epithelium of the gastrointestinal tract, and many other tissues.

Although some galectins have intracellular functions, the majority of them have extracellular activities, which facilitate their contribution to cell adhesion, cell activation, and inflammation. Galectin-3 (Gal-3) is a unique pentamer of the galectins family and it is involved in both physiological functions; cell growth and differentiation, and pathological conditions; inflammation, fibrosis, and metastasis.

Regarding pregnancy, Gal-3 is proved to participate in angiogenesis, embryo developmental processes, and modulation of maternal immunity.

Study Design

Study Type
Observational
Observational Model
Case Crossover
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
20 Years to 40 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Pregnant women between 28-32 weeks.
  • Age between 20-40 years.
  • Singleton pregnancy.
  • Women with suspicion of placenta accreta
  • Cases with mild vaginal bleeding or not having any vaginal bleeding.

Exclusion Criteria

  • Women are known to have any medical disorders.
  • Patients with known bleeding disorders or on anticoagulant therapy.
  • Patients refuse to participate.

Outcomes

Primary Outcomes

Galactin 3 level in the blood

Time Frame: 6 weeks

measured by ng/ml

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Mohammed Khairy Ali

Assistant professor

Assiut University

Study Sites (1)

Loading locations...

Similar Trials

Galectin-3 and Placenta Accreta | Clinical Trial